STOCK TITAN

Biolase Stock Price, News & Analysis

BIOLQ OTC Link

Company Description

BIOLASE INC (BIOLQ) is associated with BIOLASE, a company described as the world's leading innovator in dental laser technology. According to company statements, BIOLASE focuses on manufacturing high-performance dental laser systems that advance dentistry and improve patient experiences, with a legacy spanning more than three decades.

BIOLASE operates in the healthcare sector with a focus on medical devices, particularly dental lasers used in periodontal, implant, and other dental procedures. Its technology is presented as a foundation for minimally invasive dentistry, emphasizing patient comfort and clinical outcomes. Company materials highlight that BIOLASE has played a role in the evolution of laser-based dental treatments over many years.

Business focus and technology

BIOLASE describes itself as a global leader in dental laser technology, with systems designed for all-tissue applications in dentistry. The company highlights Er,Cr:YSGG laser technology as a core platform, used in periodontal and implant care and in protocols for periodontitis treatment. BIOLASE states that its systems are intended to support predictable clinical results, efficiency for clinicians, and improved patient comfort.

In company communications, BIOLASE emphasizes minimally invasive treatment pathways and the use of YSGG laser technology in procedures such as periodontal pocket management, bacterial decontamination, and osseous contouring, as described in its educational and conference materials. These uses are framed as part of modern periodontics and implant dentistry.

Corporate developments and ownership

BIOLASE has reported that it was founded over 35 years ago and has been active in dental laser innovation for multiple decades. The company has publicly stated that it introduced dental laser systems under the Waterlase name, which it associates with improvements in patient comfort and clinical outcomes.

According to a company announcement, BIOLASE entered a new phase after its acquisition by MegaGen Implant. BIOLASE characterizes this change in ownership as a transition that supports continued operation of the business, with an emphasis on renewed focus on innovation, quality, and customer service. The company describes this as a revitalization under new leadership, while maintaining its focus on dental laser technology.

Products and clinical applications

In public materials, BIOLASE refers to high-performance dental laser systems and all-tissue laser platforms. It highlights Er,Cr:YSGG-based systems and Waterlase-branded devices in the context of periodontal and implant care, periodontitis treatment protocols, and other minimally invasive dental procedures. The company associates these systems with goals such as reduced bleeding and swelling, less postoperative discomfort, and faster procedures compared with certain traditional surgical techniques, based on referenced clinical research.

BIOLASE also emphasizes education and clinical training as part of its presence at professional meetings. Company communications describe lectures, live demonstrations, and hands-on sessions that present YSGG laser protocols, clinical advantages in periodontal and implant procedures, and approaches to integrating all-tissue laser technology into dental practices.

Industry role

Within the broader healthcare and medical devices space, BIOLASE positions itself specifically within dental devices and laser dentistry. Its communications focus on minimally invasive dentistry, periodontal and implant care, and the use of laser systems as tools for modern dental practice. Over its multi-decade history, as described by the company, BIOLASE has aimed to define and expand the role of laser technology in clinical dentistry.

FAQs about BIOLASE (BIOLQ)

Stock Performance

$—
0.00%
0.00
Last updated:
-100%
Performance 1 year

SEC Filings

No SEC filings available for Biolase.

Financial Highlights

Revenue (TTM)
Net Income (TTM)
Operating Cash Flow

Upcoming Events

Short Interest History

Last 12 Months
Loading short interest data...

Short interest in Biolase (BIOLQ) currently stands at 13.0 thousand shares, representing 0.0% of the float. Over the past 12 months, short interest has increased by 42.4%. This relatively low short interest suggests limited bearish sentiment. With 1000.0 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.

Days to Cover History

Last 12 Months
Loading days to cover data...

Days to cover for Biolase (BIOLQ) currently stands at 1000.0 days, up 725.1% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 99899% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.

Frequently Asked Questions

What is the current stock price of Biolase (BIOLQ)?

The current stock price of Biolase (BIOLQ) is $0.000001 as of March 6, 2026.

What is the market cap of Biolase (BIOLQ)?

The market cap of Biolase (BIOLQ) is approximately 3.7K. Learn more about what market capitalization means .

What does BIOLASE INC (BIOLQ) focus on in the healthcare sector?

BIOLASE INC (BIOLQ) is associated with BIOLASE, which describes itself as the world's leading innovator in dental laser technology. The company focuses on manufacturing high-performance dental laser systems that advance dentistry and improve patient experiences.

In which industry is BIOLASE INC (BIOLQ) classified?

BIOLASE INC (BIOLQ) is classified in the medical devices industry within the healthcare sector, with a specific emphasis on dental laser technology and laser-based dental treatments.

How does BIOLASE describe its dental laser technology?

BIOLASE describes its dental laser technology as high-performance systems that support minimally invasive dentistry. Company materials highlight Er,Cr:YSGG laser platforms and all-tissue laser systems designed to enhance clinical outcomes and patient comfort.

What clinical areas does BIOLASE emphasize for its laser systems?

BIOLASE emphasizes periodontal and implant care, as well as periodontitis treatment protocols. Company communications describe the use of YSGG laser technology in periodontal pocket management, bacterial decontamination, and osseous contouring in modern periodontics.

What does BIOLASE say about its history in dental laser innovation?

BIOLASE states that it has a legacy of over three decades in dental laser technology and that it was founded over 35 years ago. The company credits itself with revolutionizing dentistry through the introduction of dental laser systems under the Waterlase name.

Has BIOLASE reported any significant ownership changes?

Yes. BIOLASE has announced that it was acquired by MegaGen Implant. The company describes this acquisition as a new chapter that supports its continued operation and a renewed commitment to innovation, quality, and customer service.

How does BIOLASE present the benefits of its laser systems for patients?

In its communications, BIOLASE associates its laser systems with goals such as less bleeding, swelling, and postoperative discomfort, faster procedures, and improved patient-reported outcomes, referencing clinical research and professional guidelines.

What role do professional conferences play in BIOLASE’s activities?

BIOLASE highlights participation in professional meetings and conferences, where it offers lectures, featured sessions, and hands-on demonstrations. These events focus on YSGG laser protocols, periodontal and implant applications, and integrating all-tissue laser technology into dental practice.